Effects of KW-5617 (zaldaride maleate), a potent and selective calmodulin inhibitor, on secretory diarrhea and on gastrointestinal propulsion in rats

Japanese Journal of Pharmacology
N Aikawa, A Karasawa

Abstract

KW-5617 (zaldaride maleate), 1,3-dihydro-1-[1-[(4-methyl-4H,6H-pyrrolo[1,2-a][4,1]-benzoxazepin -4-yl)methyl]-4-piperidinyl]-2H-benzimidazol-2-one maleate, is a selective calmodulin inhibitor. We studied the effects of KW-5617 on secretory diarrhea and gastrointestinal propulsion in rats, as compared with those of loperamide, a conventional anti-diarrheal drug. Diarrhea was induced in rats either by 16,16-dimethyl prostaglandin E2 (500 microg/kg, i.p.) or by castor oil (1 ml/100 g body weight, p.o.). In the 16,16-dimethyl prostaglandin E2 model, KW-5617 at the doses of 3 mg/kg (p.o.) and higher ameliorated the diarrhea. Similarly, loperamide improved the diarrhea, the activity of loperamide being equivalent to that of KW-5617. In the castor oil model, KW-5617 significantly delayed the onset of diarrhea at the doses of 3 mg/kg (p.o.) and higher, while loperamide delayed the onset of diarrhea at the doses of 0.3 mg/kg (p.o.) and higher. KW-5617 only at the high doses of 30 and 100 mg/kg (p.o.) reduced gastric emptying, small intestinal propulsion, proximal colonic propulsion and distal colonic propulsion. In contrast, loperamide at its anti-diarrheal doses inhibited gastrointestinal propulsion. Our results show that KW-5617, unli...Continue Reading

References

Sep 27, 1979·Biochemical and Biophysical Research Communications·P Y Wong, W Y Cheung
Aug 1, 1991·European Journal of Clinical Investigation·S Moncada, E A Higgs
Jul 23, 1991·European Journal of Pharmacology·W K MacNaughton, D G Gall
Aug 1, 1986·The Journal of Pharmacy and Pharmacology·F CapassoV Romano
Jun 1, 1985·Cell Calcium·S MacNeilS Tomlinson
Jan 30, 1982·Lancet·J E MerrittS Tomlinson
Mar 12, 1982·European Journal of Pharmacology·J H ZaveczT O Yellin
Jan 17, 1983·European Journal of Biochemistry·B M AmiranoffG E Rosselin
Apr 1, 1993·British Journal of Pharmacology·N MascoloF Capasso
May 1, 1994·Cell and Tissue Research·S J WeinmanD P Rainteau
Apr 1, 1993·The Biochemical Journal·J A Burgers, J W Akkerman
Nov 1, 1995·British Journal of Pharmacology·C T Taylor, A W Baird
Nov 15, 1996·The Journal of Physiology·M E LangJ B Meddings
May 31, 1979·Nature·A Ilundain, R J Naftalin

❮ Previous
Next ❯

Citations

Jul 18, 2002·Japanese Journal of Pharmacology·Takaharu SaitoHideo Kato
Dec 21, 2005·The Journal of Immunology : Official Journal of the American Association of Immunologists·Erqiu LiSteven M Singer

❮ Previous
Next ❯

Related Concepts

Related Feeds

Autoimmune Polyendocrinopathies

Autoimmune polyendocrinopathies, also called polyglandular autoimmune syndromes (PGASs), or polyendocrine autoimmune syndromes(PASs), are a heterogeneous group of rare diseases characterized by autoimmune activity against more than one endocrine organ, although non-endocrine organs can be affected. Discover the latest research on autoimmune polyendocrinopathies here.

Anthelmintics

Anthelmintics or antihelminthics are a group of antiparasitic drugs that expel parasitic worms (helminths) and other internal parasites from the body by either stunning or killing them and without causing significant damage to the host. Discover the latest research on anthelmintics here.